Surgery Partners (NASDAQ:SGRY) Rating Reiterated by Benchmark

Benchmark reissued their buy rating on shares of Surgery Partners (NASDAQ:SGRY) in a research note published on Wednesday morning, Benzinga reports. Benchmark currently has a $50.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Citigroup cut their target price on Surgery Partners from $43.00 to $42.00 and set a buy rating on the stock in a research report on Tuesday, February 27th. Cantor Fitzgerald reissued an overweight rating and set a $43.00 target price on shares of Surgery Partners in a research report on Wednesday, April 10th. Royal Bank of Canada reaffirmed an outperform rating and set a $49.00 price target on shares of Surgery Partners in a research report on Thursday, February 29th. Barclays assumed coverage on Surgery Partners in a research report on Wednesday, March 6th. They set an equal weight rating and a $35.00 price target on the stock. Finally, StockNews.com raised Surgery Partners from a sell rating to a hold rating in a research report on Thursday, March 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Surgery Partners has a consensus rating of Moderate Buy and a consensus target price of $43.63.

Surgery Partners Stock Performance

Shares of SGRY opened at $24.53 on Wednesday. The stock has a 50-day simple moving average of $27.63 and a 200-day simple moving average of $29.73. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.57 and a current ratio of 1.71. The stock has a market capitalization of $3.12 billion, a PE ratio of -245.30, a PEG ratio of 2.25 and a beta of 2.75. Surgery Partners has a 1 year low of $22.05 and a 1 year high of $45.79.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, February 26th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Surgery Partners had a positive return on equity of 3.65% and a negative net margin of 0.43%. The business had revenue of $735.40 million for the quarter, compared to analyst estimates of $741.93 million. During the same quarter last year, the company earned $0.22 EPS. The business’s quarterly revenue was up 4.0% on a year-over-year basis. On average, analysts predict that Surgery Partners will post 0.78 earnings per share for the current fiscal year.

Insider Activity at Surgery Partners

In related news, CEO Jason Eric Evans sold 5,780 shares of Surgery Partners stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $35.08, for a total value of $202,762.40. Following the sale, the chief executive officer now directly owns 419,118 shares in the company, valued at $14,702,659.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Surgery Partners news, CEO Jason Eric Evans sold 5,780 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.08, for a total transaction of $202,762.40. Following the sale, the chief executive officer now directly owns 419,118 shares in the company, valued at $14,702,659.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Bradley R. Owens sold 1,040 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.22, for a total value of $36,628.80. Following the sale, the insider now owns 73,149 shares in the company, valued at $2,576,307.78. The disclosure for this sale can be found here. Insiders have sold a total of 14,831 shares of company stock worth $482,609 over the last three months. 2.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Surgery Partners

A number of institutional investors have recently made changes to their positions in the stock. Mesirow Institutional Investment Management Inc. raised its holdings in shares of Surgery Partners by 12.4% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 3,388 shares of the company’s stock worth $108,000 after acquiring an additional 373 shares during the last quarter. Amalgamated Bank raised its holdings in shares of Surgery Partners by 7.6% in the third quarter. Amalgamated Bank now owns 9,948 shares of the company’s stock worth $291,000 after acquiring an additional 701 shares during the last quarter. Raymond James & Associates raised its holdings in shares of Surgery Partners by 1.2% in the third quarter. Raymond James & Associates now owns 61,188 shares of the company’s stock worth $1,790,000 after acquiring an additional 736 shares during the last quarter. Natixis Advisors L.P. raised its holdings in shares of Surgery Partners by 8.6% in the fourth quarter. Natixis Advisors L.P. now owns 11,735 shares of the company’s stock worth $375,000 after acquiring an additional 934 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Surgery Partners by 69.7% in the third quarter. Nisa Investment Advisors LLC now owns 2,945 shares of the company’s stock worth $86,000 after acquiring an additional 1,210 shares during the last quarter.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.